Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
rituximab monotherapy
DRUG
2 trials
Sponsors
Charite University, Berlin, Germany
, Beijing Friendship Hospital
Conditions
Chronic Active Epstein-Barr Virus Infection
PTLD
Posttransplant Lymphoproliferative Disorder
Secondary Hemophagocytic Lymphohistiocytosis
Phase 2
Risk Stratified Sequential Treatment for CD20-positive PTLD
Completed
NCT00590447
Charite University, Berlin, Germany
Posttransplant Lymphoproliferative Disorder, PTLD
Start: 2006-12-31
End: 2015-07-31
Updated: 2017-03-07
Phase 3
Rituximab Monotherapy for EBV-HLH and CAEBV
NCT05384743
Beijing Friendship Hospital
Chronic Active Epstein-Barr Virus Infection, Secondary Hemophagocytic Lymphohistiocytosis
Start: 2022-02-01
End: 2024-04-01
Target: 30
Updated: 2022-05-20
Related Papers
Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients
Blood
2015-12-03
6 citations
Fc<b><i>γ</i></b>-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder
Journal of Immunology Research
2014-01-01
3 citations